Skip to main content

Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Role of biomarkers in early infectious complications after lung transplantation.

PMID: 28704503
Journal: PLoS One
Year: 2017
Reference: PLoS One. 2017 Jul 13;12(7):e0180202. doi: 10.1371/journal.pone.0180202. eCollection 2017.
Impact factor:
Publication type: Paper in international publication
Authors: Garcia Campos, Ascension; Iranzo, Reyes; Minambres, Eduardo; Rellan, Luzdivina; Riera, Jordi; Robles, Juan Carlos; Santibanez, Miguel; Suberviola, Borja; Vicente, Rosario et al.
DOI: 10.1371/journal.pone.0180202

Role of intraluminal bowel echogenicity on prenatal ultrasounds to determine the anatomical level of intestinal atresia.

PMID: 27023781
Journal: Journal of Maternal-Fetal & Neonatal Medicine
Year: 2017
Reference: J Matern Fetal Neonatal Med. 2017 Jan;30(1):103-108. doi: 10.3109/14767058.2016.1163677. Epub 2016 Mar 29.
Impact factor: 1.674
Publication type: Paper in international publication
Authors: Goruppi, Ilaria, Arevalo, Silvia, Gander, Romy, Molino, Jose-Andres, Oria, Marc, Carreras, Elena, Peiro, Jose-Luis et al.
DOI: 10.3109/14767058.2016.1163677

Role of intraluminal bowel echogenicity on prenatal ultrasounds to determine the anatomical level of intestinal atresia.

PMID: 27023781
Journal: Journal of Maternal-Fetal & Neonatal Medicine
Year: 2017
Reference: J Matern Fetal Neonatal Med. 2017 Jan;30(1):103-108. doi: 10.3109/14767058.2016.1163677. Epub 2016 Mar 29.
Impact factor:
Publication type: Paper in international publication
Authors: Arevalo, Silvia; Carreras, Elena; Gander, Romy; Goruppi, Ilaria; Molino, Jose-Andres; Oria, Marc; Peiro, Jose-Luis et al.
DOI: 10.3109/14767058.2016.1163677

Role of Parp Activity in Lung Cancer-induced Cachexia: Effects on Muscle Oxidative Stress, Proteolysis, Anabolic Markers and Phenotype.

PMID: 28177129
Journal: JOURNAL OF CELLULAR PHYSIOLOGY
Year: 2017
Reference: J Cell Physiol. 2017 Dec;232(12):3744-3761. doi: 10.1002/jcp.25851. Epub 2017 Apr 27.
Impact factor: 4.08
Publication type: Paper in international publication
Authors: Garcia-Arumi, Elena, Chacon-Cabrera, Alba, Mateu-Jimenez, Merce, Langohr, Klaus, Fermoselle, Clara, Barreiro, Esther, Yelamos, Jose, Andreu, Antoni L et al.
DOI: 10.1002/jcp.25851

Role of Parp Activity in Lung Cancer-induced Cachexia: Effects on Muscle Oxidative Stress, Proteolysis, Anabolic Markers and Phenotype.

PMID: 28177129
Journal: JOURNAL OF CELLULAR PHYSIOLOGY
Year: 2017
Reference: J Cell Physiol. 2017 Dec;232(12):3744-3761. doi: 10.1002/jcp.25851. Epub 2017 Apr 27.
Impact factor:
Publication type: Paper in international publication
Authors: Andreu, Antoni L; Barreiro, Esther; Chacon-Cabrera, Alba; Fermoselle, Clara; Garcia-Arumi, Elena; Langohr, Klaus; Mateu-Jimenez, Merce; Yelamos, Jose et al.
DOI: 10.1002/jcp.25851

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

PMID: 28254641
Journal: BREAST
Year: 2017
Reference: Breast. 2017 Jun;33:8-13. doi: 10.1016/j.breast.2017.02.011. Epub 2017 Feb 28.
Impact factor: 2.801
Publication type: Paper in international publication
Authors: Peg, Vicente, Sansano, Irene, Vieites, Begona, Bernet, Laia, Cano, Rafael, Cordoba, Alicia, Sancho, Magdalena, Martin, Maria Dolores, Vilardell, Felip, Cazorla, Alicia et al.
DOI: 10.1016/j.breast.2017.02.011

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

PMID: 28254641
Journal: BREAST
Year: 2017
Reference: Breast. 2017 Jun;33:8-13. doi: 10.1016/j.breast.2017.02.011. Epub 2017 Feb 28.
Impact factor:
Publication type: Paper in international publication
Authors: Bernet, Laia; Cano, Rafael; Cazorla, Alicia; Cordoba, Alicia; Cortes, Javier; Espinosa-Bravo, Martin; Martin, Maria Dolores; Peg, Vicente; Perez-Garcia, Jose Manuel; Ramon Y Cajal, Santiago et al.
DOI: 10.1016/j.breast.2017.02.011

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

PMID: 28916367
Journal: LANCET
Year: 2017
Reference: Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
Impact factor: 47.831
Publication type: Paper in international publication
Authors: Bologna, A, Coleman, Robert L, Oza, Amit M, Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I, Clamp, Andrew et al.
DOI: 10.1016/S0140-6736(17)32440-6

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

PMID: 28916367
Journal: LANCET
Year: 2017
Reference: Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
Impact factor:
Publication type: Paper in international publication
Authors: Aghajanian, C; Aghajanian, Carol; Amit, A; Armstrong, D K; Armstrong, Deborah K; Banerjee, S N; Birrer, M J; Bologna, A; Buck, M; Buss, M K et al.
DOI: 10.1016/S0140-6736(17)32440-6

Rufinamide in children and adults in routine clinical practice.

PMID: 26923380
Journal: ACTA NEUROLOGICA SCANDINAVICA
Year: 2017
Reference: Acta Neurol Scand. 2017 Jan;135(1):122-128. doi: 10.1111/ane.12572. Epub 2016 Feb 29.
Impact factor: 3.087
Publication type: Paper in international publication
Authors: Jaraba, S, Santamarina, E, Miro, J, Toledo, M, Molins, A, Burcet, J, Becerra, J L, Raspall, M, Pico, G, Miravet, E et al.
DOI: 10.1111/ane.12572

Rufinamide in children and adults in routine clinical practice.

PMID: 26923380
Journal: ACTA NEUROLOGICA SCANDINAVICA
Year: 2017
Reference: Acta Neurol Scand. 2017 Jan;135(1):122-128. doi: 10.1111/ane.12572. Epub 2016 Feb 29.
Impact factor:
Publication type: Paper in international publication
Authors: Becerra, J L; Burcet, J; Cano, A; Falip, M; Fernandez, S; Fossas, P; Jaraba, S; Miravet, E; Miro, J; Molins, A et al.
DOI: 10.1111/ane.12572

Ruling in and ruling out with elastography in compensated advanced chronic liver disease.

PMID: 27015870
Journal: GUT
Year: 2017
Reference: Gut. 2017 Jan;66(1):197-198. doi: 10.1136/gutjnl-2016-311775. Epub 2016 Mar 25.
Impact factor: 14.921
Publication type: Paper in international publication
Authors: Augustin, Salvador, Pons, Monica, Genesca, Joan et al.
DOI: 10.1136/gutjnl-2016-311775

Ruling in and ruling out with elastography in compensated advanced chronic liver disease.

PMID: 27015870
Journal: GUT
Year: 2017
Reference: Gut. 2017 Jan;66(1):197-198. doi: 10.1136/gutjnl-2016-311775. Epub 2016 Mar 25.
Impact factor:
Publication type: Paper in international publication
Authors: Augustin, Salvador; Genesca, Joan; Pons, Monica et al.
DOI: 10.1136/gutjnl-2016-311775

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

PMID: 29284010
Journal: PLoS One
Year: 2017
Reference: PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.
Impact factor: 2.806
Publication type: Paper in international publication
Authors: Han, Sae-Won, O'Neil, Bert H, Wallmark, John M, Lorente, David, Elez, Elena, Raimbourg, Judith, Ejadi, Samuel, Piha-Paul, Sarina A, Stein, Mark N, Abdul Razak, Albiruni R et al.
DOI: 10.1371/journal.pone.0189848

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

PMID: 29284010
Journal: PLoS One
Year: 2017
Reference: PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.
Impact factor:
Publication type: Paper in international publication
Authors: Abdul Razak, Albiruni R; Cohen, Roger B; Dotti, Katia; Ejadi, Samuel; Elez, Elena; Gomez-Roca, Carlos; Gould, Marlena; Han, Sae-Won; Lorente, David; O'Neil, Bert H et al.
DOI: 10.1371/journal.pone.0189848

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

PMID: 28802814
Journal: The lancet. Gastroenterology & hepatology
Year: 2017
Reference: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.
Impact factor: 0
Publication type: Clinical Trials
Authors: Lawitz, Eric, Buti, Maria, Vierling, John M, Almasio, Piero L, Bruno, Savino, Ruane, Peter J, Hassanein, Tarek I, Muellhaupt, Beat, Pearlman, Brian, Jancoriene, Ligita et al.
DOI: 10.1016/S2468-1253(17)30163-2

Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials.

PMID: 28802814
Journal: The lancet. Gastroenterology & hepatology
Year: 2017
Reference: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10.
Impact factor:
Publication type: Clinical Trials
Authors: Almasio, Piero L; Barr, Eliav; Bruno, Savino; Buti, Maria; Butterton, Joan R; Dutko, Frank J; Fernsler, Doreen; Gao, Wei; Grandhi, Anjana; Hassanein, Tarek I et al.
DOI: 10.1016/S2468-1253(17)30163-2

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

PMID: 28802816
Journal: The lancet. Gastroenterology & hepatology
Year: 2017
Reference: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.
Impact factor: 0
Publication type: Clinical Trials
Authors: Su, Feng-Hsiu, Wan, Shuyan, Zeng, Zhen, Chen, Huei-Ling, Dutko, Frank J, Nguyen, Bach-Yen T, Wahl, Janice, Robertson, Michael N, Barr, Eliav, Yeh, Wendy W et al.
DOI: 10.1016/S2468-1253(17)30159-0

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.

PMID: 28802816
Journal: The lancet. Gastroenterology & hepatology
Year: 2017
Reference: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10.
Impact factor:
Publication type: Clinical Trials
Authors: Agarwal, Kosh; Barr, Eliav; Ben-Ari, Ziv; Butterton, Joan R; Chen, Huei-Ling; Dutko, Frank J; Esteban, Rafael; Fernsler, Doreen; Fitzgerald, Brian; Foster, Graham R et al.
DOI: 10.1016/S2468-1253(17)30159-0

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

PMID: 29066163
Journal: LANCET NEUROLOGY
Year: 2017
Reference: Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20.
Impact factor: 26.284
Publication type: Paper in international publication
Authors: D'Hondt, Ann, Garcia, Alejandra Dalila, Lamont, Phillipa, Leong, Wai-Kuen, Boterhoven, Heidi, Fyfe, Beverly, Roberts, Leslie, Jasinarachchi, Mahi, Willlems, Natasha, Wanschitz, Julia et al.
DOI: 10.1016/S1474-4422(17)30369-1

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

PMID: 29066163
Journal: LANCET NEUROLOGY
Year: 2017
Reference: Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20.
Impact factor:
Publication type: Paper in international publication
Authors: Abramov, Vladislav; Acar, Nazire Pinar; Agopian, Eliz; Agriesti, Julie; Akhter, Salma; Akiyama, Tetsuya; Alberti Aguilo, Maria; Alboini, Paolo Emilio; Alcon, Karan; Alsharabati, Mohammad et al.
DOI: 10.1016/S1474-4422(17)30369-1

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

PMID: 28229893
Journal: LANCET NEUROLOGY
Year: 2017
Reference: Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15.
Impact factor: 26.284
Publication type: Paper in international publication
Authors: Elkins, Jacob, Veltkamp, Roland, Montaner, Joan, Johnston, S Claiborne, Singhal, Aneesh B, Becker, Kyra, Lansberg, Maarten G, Tang, Weihua, Chang, Ih, Muralidharan, Kumar et al.
DOI: 10.1016/S1474-4422(16)30357-X

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

PMID: 28229893
Journal: LANCET NEUROLOGY
Year: 2017
Reference: Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15.
Impact factor:
Publication type: Paper in international publication
Authors: Becker, Kyra; Chang, Ih; Elkind, Mitchell S V; Elkins, Jacob; Gheuens, Sarah; Johnston, S Claiborne; Lansberg, Maarten G; Mehta, Lahar; Montaner, Joan; Muralidharan, Kumar et al.
DOI: 10.1016/S1474-4422(16)30357-X

Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon gamma release assay and the tuberculin skin test: a phase 3, double-blind, randomised, controlled trial.

PMID: 28159608
Journal: Lancet Respiratory Medicine
Year: 2017
Reference: Lancet Respir Med. 2017 Apr;5(4):259-268. doi: 10.1016/S2213-2600(16)30436-2. Epub 2017 Feb 1.
Impact factor: 19.287
Publication type: Paper in international publication
Authors: Orcau, Angels, Andersen, Peter, Cayla, Joan A, Roldan, Llanos, Miro, Jose M, Moreno, Antonio, Ruhwald, Morten, Aggerbeck, Henrik, Gallardo, Rafael Vazquez, Hoff, Soren T et al.
DOI: 10.1016/S2213-2600(16)30436-2